This is part three in a five-part series called "The Limits of Accelerating Returns" that focuses on the limitations of Ray Kurzweil's Law of Accelerating Returns when applied to molecular biology and biomedical technology, including longevity treatments. The other articles in the series are "The Limits of Accelerating Returns," "Biology is not Digital," "Some Rates are Fixed," and "Implications of Fixed Returns."
In his essay called “Making the World a Billion Times Better,” Ray Kurzweil writes, “The approximately 23,000 genes in our cells are basically software programs, and we are making exponential gains in modeling and simulating the information processes that cracking the genome code has unlocked.” The problem is that genes are only roughly analogous to software programs, as I discussed in the previous post in this series, and simulating the information processes of the genome is non-trivial in the extreme.
Let’s take a very simple example of an artificial genome called a “repressilator” that was added to bacteria as a proof-of-concept of synthetic biology and biological simulation. The repressilator’s machinery consists of three genes, each of which turns off one of the other genes. When one of the genes is active, it turns off one of the other genes. Meanwhile, the third gene is in the processing of shutting down the first. When the first gene is turned off, the second one turns on, and stats shutting down the third gene. Thus, there’s a cycle or oscillation to the activation of the genes (the name of the construct is a contraction of “repression” and “oscillation”).
The system also includes a fourth gene that produces a visible signal so that the oscillation can be tracked. This seems like a pretty straightforward system. The scientists who developed it even did a lot of modeling to figure out how to optimize the oscillations before they went to the trouble of building the thing.
But it didn’t work the way they expected.
